REGENERX BIOPHARMACEUTICALS INC
DelistedCIK 707511fmd_0REPYYTD3ME4MKNVHZEN8AHHPHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Mar 31, 2023, 52 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Research and development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Operating income | (1) | (2) | (2) | (2) | (1) | (1) | (1) | (1) | (1) | (1) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | – | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | – | – | 2 | 2 | (1) | (0) | (0) | (0) | (0) |
| Income before taxes | – | – | – | 0 | 0 | (2) | (1) | (2) | (2) | (2) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | 0 | 0 | (2) | (1) | (2) | (2) | (2) |
| Net income | (1) | (3) | (5) | 0 | 0 | (2) | (1) | (2) | (2) | (2) |
| Net income to common shareholders | – | – | – | – | – | (2) | (1) | (2) | (2) | (2) |